Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Cash Flow: 2019-2024

Historic Net Cash Flow for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$14.5 million.

  • GeneDx Holdings' Net Cash Flow rose 1101.76% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 229.49%. This contributed to the annual value of -$14.5 million for FY2024, which is 61.56% up from last year.
  • Per GeneDx Holdings' latest filing, its Net Cash Flow stood at -$14.5 million for FY2024, which was up 61.56% from -$37.6 million recorded in FY2023.
  • GeneDx Holdings' Net Cash Flow's 5-year high stood at $282.5 million during FY2021, with a 5-year trough of -$263.2 million in FY2022.
  • For the 3-year period, GeneDx Holdings' Net Cash Flow averaged around -$105.1 million, with its median value being -$37.6 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 7,044.89% in 2021, then crashed by 193.15% in 2022.
  • GeneDx Holdings' Net Cash Flow (Yearly) stood at $4.0 million in 2020, then soared by 7,044.89% to $282.5 million in 2021, then tumbled by 193.15% to -$263.2 million in 2022, then skyrocketed by 85.70% to -$37.6 million in 2023, then spiked by 61.56% to -$14.5 million in 2024.